nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.08.2008 | Original article

Biodistribution and radiation dosimetry of the A₁ adenosine receptor ligand ¹⁸F-CPFPX determined from human whole-body PET

verfasst von: Hans Herzog, David Elmenhorst, Oliver Winz, Andreas Bauer

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

¹⁸F-8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (¹⁸F-CPFPX) is a potent radioligand to study human cerebral A₁ adenosine receptors and their neuromodulatory and neuroprotective functions with positron emission tomography (PET). The purpose of this study was to determine the biodistribution and the radiation dose of ¹⁸F-CPFPX by whole-body scans in humans.

Methods

Six normal volunteers were examined with 12 whole-body PET scans from 1.5 min to 4.5 h after injection. Volumes of interest were defined over all visually identifiable organs, i.e. liver, gallbladder, kidneys, small intestines, heart, and brain to obtain the organs’ volumes and time-activity curves (TACs). TACs were fitted with exponential functions, extrapolated, multiplied with the physical decay and normalized to injected activities so that the residence times could be computed as area under the curve. Radiation doses were calculated using the OLINDA/EXM software for internal dose assessment in nuclear medicine.

Results

The liver uptake shows peak values (decay-corrected) of up to 35% of the injected radioactivity. About 30% is eliminated by bladder voiding. The highest radiation dose is received by the gallbladder (136.2 ± 66.1 μSv/MBq), followed by the liver (84.4 ± 10.6 μSv/MBq) and the urinary bladder (78.3 ± 7.1 μSv/MBq). The effective dose was 17.6 ± 0.5 μSv/MBq.

Conclusions

With 300 MBq of injected ¹⁸F-CPFPX a subject receives an effective dose (ICRP 60) of 5.3 mSv. Thus the effective dose of an ¹⁸F-CPFPX study is comparable to that of other ¹⁸F-labelled neuroreceptor ligands.

Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 2001;24:31–55.PubMedCrossRef

Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–52.PubMed

Fastbom J, Pazos A, Probst A, Palacios JM. Adenosine A1 receptors in the human brain: A quantitative autoradiographic study. Neuroscience. 1987;22:827–39.PubMedCrossRef

Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. Synapse. 1997;27:322–35.PubMedCrossRef

Bauer A, Holschbach MH, Meyer PT, et al. In vivo imaging of adenosine A1 receptors in the human brain with [¹⁸F]CPFPX and positron emission tomography. Neuroimage. 2003;19:1760–9.PubMedCrossRef

Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:375–81.PubMedCrossRef

Bauer A, Langen KJ, Bidmon H, et al. ¹⁸F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. J Nucl Med. 2005;46:450–4.PubMed

Glass M, Faull RL, Bullock JY, et al. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res. 1996;710:56–68.PubMedCrossRef

Ulas J, Brunner LC, Nguyen L, Cotman CW. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience. 1993;52:843–54.PubMedCrossRef

10.

Deckert J, Abel F, Kunig G, et al. Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity. Neurosci Lett. 1998;244:1–4.PubMedCrossRef

11.

Holschbach MH, Fein T, Krummeich C, et al. A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single photon emission tomography (SPET). J Med Chem. 1998;41:555–63.PubMedCrossRef

12.

Holschbach MH, Olsson RA, Bier D, et al. Synthesis and evaluation of no-carrieradded 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F] CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002;45:5150–6.PubMedCrossRef

13.

Herzog H, Boy C, Holschbach M, et al. Cerebral Kinetics of the A1 Adenosine Receptor Antagonist [¹⁸F]CPFPX Measured in Non-Human Primates. J Cereb Blood Flow Metab. 2003;23(Suppl.1):690.

14.

Meyer PT, Bier D, Holschbach MH, et al. Quantification of cerebral A1 adenosine receptors in humans using [¹8F]CPFPX and PET. J Cereb Blood Flow Metab. 2004;24:323–33.PubMedCrossRef

15.

Meyer PT, Elmenhorst D, Bier D, et al. Quantification of cerebral A1 adenosine receptors in humans using [¹⁸F]CPFPX and PET: an equilibrium approach. Neuroimage. 2005;24:1192–204.PubMedCrossRef

16.

Meyer PT, Elmenhorst D, Zilles K, Bauer A. Simplified quantification of cerebral A1 adenosine receptors using [¹⁸F]CPFPX and PET: analyses based on venous blood sampling. Synapse. 2005;55(4):212–23.PubMedCrossRef

17.

Elmenhorst D, Meyer PT, Winz OH, et al. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci. 2007;27:2410–5.PubMedCrossRef

18.

Boy C, Meyer PT, Kircheis G, et al. Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. Eur J Nucl Med Mol Imag. (paper accepted).

19.

Matusch A, Meyer PT, Bier D, et al. Metabolism of the A1 adenosine receptor PET ligand [¹⁸F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl Med Biol. 2006;33:891–8.PubMedCrossRef

20.

Herzog H, Holschbach M, Boy C, et al. Biodistribution and radiation dose of the new A1 adenosine receptor antagonist [F-18] CPFPX in mice and baboon. J Nucl Med. 1998;39(5):188P.

21.

Brix G, Zaers J, Adam L, et al. Performance evaluation of a whole-body PET Scanner using the NEMA protocol. J Nucl Med. 1997;38:1614–23.PubMed

22.

Lu JQ, Ichise M, Liow JS, Ghose S, Vines D, Innis RB. Biodistribution and radiation dosimetry of the serotonin transporter ligand ¹¹C-DASB determined from human whole-body PET. J Nucl Med. 2004;45:1555–9.PubMed

23.

Slifstein M, Hwang DR, Martinez D, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand ¹¹C-raclopride determined from human whole-body PET. J Nucl Med. 2006;47:313–9.PubMed

24.

Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-¹⁸F-FACBC in humans. J Nucl Med. 2007;48:1017–20.PubMedCrossRef

25.

Hoffman EJ, Huang SC, Phelps ME, Kuhl DE. Quantitation in positron emission computed tomography: 4. Effect of accidental coincidences. J Comput Assist Tomogr. 1981;5:391–400.PubMedCrossRef

26.

International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30 Part 1 (Oxford, UK: Pergamon Press), 1979.

27.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

28.

Herzog H, Zilken H, Niederbremer A, Friedrich W, Müller-Gärtner HW. Calculation of residence times and radiation doses using the standard PC-software Excel. Eur J Nucl Med. 1997;24:1514–21.PubMedCrossRef

29.

Cloutier RJ, Smith SA, Watson EE, et al. Dose to the fetus from radionuclides in the bladder. Health Physics. 1973;25:147–61.PubMedCrossRef

30.

International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. New York: Pergamon Press; 1991.

31.

International Commission on Radiological Protection. Report of the task group on reference man. ICRP Publication 23. Oxford: Pergamon Press; 1975.

32.

Food and Drug Administration. Title 21 CFR 361.1, Radioactive Drugs for Certain Research Uses. 4–1–01 ed. Washington, DC: National Archives and Records Administration; 2001:300–305.

33.

Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S–61S.PubMed

34.

Kessler RM, Mason NS, Jones C, Ansari MS, Manning RF, Price RR. [¹⁸F] N-ally-5-fluorproplepidepride (fallypride): radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. Neuroimage. 2000;6:S32.

35.

Herzog H, Coenen HH, Kuwert T, Langen KJ, Feinendegen LE. Quantitation of the whole-body distribution of PET radiopharmaceuticals: Applied to 3-N-([¹⁸F]fluoroethyl)spiperone. Eur J Nucl Med. 1990;16:77–83.PubMedCrossRef

Titel: Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET
verfasst von: Hans Herzog
David Elmenhorst
Oliver Winz
Andreas Bauer
Publikationsdatum: 01.08.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0753-x

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2008

Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology

Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels

Planar and SPECT imaging in the era of PET and PET–CT: can it survive the test of time?

Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer

Annual congress of the EANM 2007, Copenhagen, Denmark Abstracts Tuesday

Effects of AV delay programming on ventricular resynchronisation: role of radionuclide ventriculography